Corbion: Q1 2024 Interim Management Statement
26 April 2024 - 7:00AM
Corbion: Q1 2024 Interim Management Statement
Corbion, the Amsterdam-listed sustainable ingredients company
that champions preservation through the application of science,
today publishes its results for the quarter ending 31 March
2024.
Key highlights first quarter of 2024
- Organic growth core activities:
- Sales: volume/mix +1.7%, price -4.5%
- Adjusted EBITDA: +0.7%
- Adjusted EBITDA margin 13.8% (+ 50bps versus last year)
- Sales € 344.3 million; an organic decrease of -3.4%
- Adjusted EBITDA € 47.2 million; an organic decrease of
-1.2%
- Positive Free Cash Flow € 7.5 million
- Double digit growth in sales and Adjusted EBITDA in Health
& Nutrition
- TotalEnergies Corbion joint venture: sales € 31.6 million; an
organic growth of 24.3%
- Divestment of non-core US Emulsifier business completed on
April 1st
- Share buyback program of € 20.0 million and special cash
dividend of € 0.10 per share
- Confirmation of FY24 outlook
€ million |
Q1 2024 |
Q1 2023 |
Total growth |
Organic growth |
Sales |
344.3 |
359.6 |
-4.3% |
-3.4% |
Adjusted EBITDA |
47.2 |
48.4 |
-2.5% |
-1.2% |
|
|
|
|
|
Core activities |
|
|
|
|
Sales |
300.9 |
312.5 |
-3.7% |
-2.8% |
Adjusted EBITDA |
41.4 |
41.6 |
-0.5% |
0.7% |
Commenting on today’s results, Olivier Rigaud, CEO, said:
“I am pleased to see positive volume/mix growth and organic
Adjusted EBITDA growth in our core activities as well as a
continuation of our positive free cash flow delivery. We made good
progress in the implementation of our restructuring program
including mothballing our plant in Peoria, US intended to increase
free cash flow and margins going forward. Building on Corbion's
first-quarter performance, we are on-track to deliver in line with
our full year guidance.
In Functional Ingredients & Solutions, we saw continued
positive momentum in our Food segment leading to volume/mix growth
in the first quarter in this segment. As previously indicated, the
non-food segment is facing temporarily softness in some markets,
including semiconductors. In line with our earlier guidance,
pricing has been lower as a result of price reductions in some
areas following input cost relaxation. In Health & Nutrition,
we continue to see strong double digit growth in both sales and
adjusted EBITDA mainly driven by the Nutrition segment (Omega-3 DHA
within aquaculture and pet nutrition).
Upon the completion of the commissioning phase of our new
circular lactic acid plant in Thailand, we have entered the
start-up phase and expect production to gradually ramp up.
On April 1st, we completed the divestment of the non-core US
Emulsifier business. As a result, we have decided on a share
buyback program of € 20 million and a special cash dividend of €
0.10 per share in line with our capital allocation priorities,
leaving sufficient bandwidth for investments to support continued
growth".
- 20240426 Corbion 1Q24 press release Final
Corbion N.V (EU:CRBN)
Historical Stock Chart
Von Nov 2024 bis Dez 2024
Corbion N.V (EU:CRBN)
Historical Stock Chart
Von Dez 2023 bis Dez 2024